Perrigo Banner

Product Search Results

5 products match your search.
Lansoprazole Delayed-Release Capsules, 15mg
Compare to the Active Ingredient of: Prevacid® 24HR
Levocetirizine Dihydrochloride Oral Solution 2.5 mg/5 mL (0.5 mg/mL)
Generic to: Xyzal®
Levocetirizine Dihydrochloride Tablets 5mg
Generic to: Xyzal®
Loratadine Tablets, 10 mg
Compare to the Active Ingredient of: Claritin®
Loratadine-D 12 Hour Pseudoephedrine Sulfate 120 mg/Loratadine 5 mg Extended Release Tablets
Compare to the Active Ingredient of: Claritin-D® 12 Hour
Teature Clindamycin and Benzoyl Peroxide Topical Gel
Generic DPP4i
Important Safety Information
  • Alogliptin is contraindicated in patients with a history of serious hypersensitivity reaction to alogliptin-containing products such as anaphylaxis, angioedema, or severe cutaneous adverse reactions.
  • Acute pancreatitis: There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue Alogliptin.
  • Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with Alogliptin such as anaphylaxis, angioedema or severe cutaneous adverse reactions. In such cases, promptly discontinue Alogliptin, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes. Use caution in a patient with a history of angioedema with another DPP-4i because it is unknown whether such patients will be predisposed to angioedema.
  • Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal. Causality cannot be excluded. Baseline liver test panel is recommended. If liver injury is detected, promptly interrupt Alogliptin and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart Alogliptin if liver injury is confirmed and no alternative etiology can be found.
  • Hypoglycemia: Insulin and insulin secretagogues are known to cause hypoglycemia. A lower dose of the insulin or insulin secretagogue may be required to minimize the risk when used in combination with Alogliptin.
  • Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors. Consider as a possible cause for severe joint pain and discontinue drug if appropriate.
  • Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Alogliptin or any other anti-diabetic drug.
  • Most common adverse reactions (4% of patients treated with Alogliptin 25 mg and more frequently than in patients who received placebo) were nasopharyngitis (4.4%), headache (4.2%), and upper respiratory tract infection (4.2%).

Patients taking Alogliptin should contact their health care professionals right away if they develop signs and symptoms of heart failure such as:

  • Unusual shortness of breath during daily activities
  • Trouble breathing when lying down
  • Tiredness, weakness, or fatigue
  • Weight gain with swelling in the ankles, feet, legs, or stomach Patients should not stop taking their medicine without first talking to their health care professionals.

Patients should not stop taking their medicine without first talking to their health care professionals.


Alogliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin is not for treatment of type 1 diabetes or diabetic ketoacidosis.

Please see Full Prescribing Information, including Medication Guide for Alogliptin.

©2016 Perrigo Company, plc

check patient preferred tier status and lower generic co-pay options
Perrigo on Facebook Perrigo on Twitter Perrigo on YouTube Perrigo on LinkedIn Perrigo RSS